atrial fibrillation
Conditions
Interventions
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 65, regardless of gender; 2. High risk patients with atrial fibrillation confirmed by clinical examination; 3. Atrial fibrillation CHADS2 score >= 2; 4. The expected survival time was more than 12 weeks; 5. Hemoglobin >= 90g / L, platelet (PLT) >= 75 x 10^9 / L, platelet (PLT) >= 75 x 10^9 / L; 6. Leukocytes (WBC) >= 3.0 x 10^9 / L, neutrophils (ANC) >= 1.5 x 10^9 / L; 7. Patients voluntarily used noac (rivaroxaban) regimen, regardless of whether they had used new anticoagulants in the past; 8. Combination therapy is allowed; 9. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who can not be given oral administration; 2. Severe hepatic and renal insufficiency, or recent history of myocardial infarction (within 3 months); 3. Patients with severe uncontrolled medical diseases or acute infection (infection causes fever above 38 degrees C); 4. Pregnant or lactating women or fertile (male or female with menopause less than 1 year) are unwilling to take contraceptive measures; 5. Patients with known allergy to rivaroxaban; 6. The patients who were not suitable for the clinical trial were determined by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adherence; | — |
Secondary
| Measure | Time frame |
|---|---|
| CHA2DS2-VASc scores; | — |
Countries
China
Contacts
Public ContactXiaoyang Liao
West China Hospital, Sichuan University
Outcome results
None listed